TrialDiabetologia2016

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.

Lennart Tonneijck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.